U.S., Aug. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07110740) titled 'Bioequivalence Study Between UI009 and UIC202005 in Healthy Subjects' on July 21.
Brief Summary: A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Evaluate Bioequivalence After Dry-powder Inhalation of UIC202005 or UI009 in Healty Volunteers
Study Start Date: Oct. 24, 2024
Study Type: INTERVENTIONAL
Condition:
Health
Intervention:
DRUG: UI009
inhale UI009 twice a day on Day 1 and Day 8.
DRUG: UIC202005
inhale UIC202005 twice a day on Day 1 and Day 8.
Recruitment Status: COMPLETED
Sponsor: Korea United Pharm. Inc.
Disclaimer: Curated by HT Syndication....